How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls

27 Feb 2020

The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.

No strings attached — Trump Administration Will Not Dictate Prices Despite Concerns From House Democrats

How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls

More from Drug Pricing

More from Scrip